Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: practical guidelines and current issues.
Neoadjuvant chemoradiotherapy is being increasingly offered to patients with invasive esophageal carcinoma in an effort to downstage the tumor and consequently increase the rate of curative resection. A substantial amount of data has suggested that pathologic tumor regression following neoadjuvant therapy is an important predictor of local recurrence and long-term survival in esophageal cancer. Therefore, it is important that these posttreatment resection specimens are handled in a standardized manner and a reproducible method of tumor regression grading is used. Pathologic examination of such specimens is not straightforward, and, in fact, it presents a particular challenge to pathologists, especially when a good response to neoadjuvant therapy has been achieved and little or no residual tumor remains. We provide some guidelines for handling and reporting such specimens and outline the commonly used tumor regression grading systems for posttreatment esophagectomy specimens.
Chang
Fuju
F
Department of Histopathology, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, London, England.
Deere
Harriet
H
Mahadeva
Ula
U
George
Simi
S
D002277:Carcinoma / Q000473:pathology* / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000473:pathology* / Q000628:therapy*; D016629:Esophagectomy; D006801:Humans; D018365:Neoplasm, Residual / Q000473:pathology*; D017410:Practice Guidelines as Topic; D018714:Radiotherapy, Adjuvant; D013048:Specimen Handling; D016896:Treatment Outcome